Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?

JAMA Pediatr. 2020 Jan 1;174(1):15-16. doi: 10.1001/jamapediatrics.2019.4509.

Author

Affiliation

¹ Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.

PMID: 31764954
DOI: 10.1001/jamapediatrics.2019.4509

No abstract available

Publication types

Editorial
Comment

MeSH terms

Asthma*
Child
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Medical Overuse
Omalizumab / therapeutic use

Substances

Omalizumab